Clinical trials: Sitagliptin, completed
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
This is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, PK and PD of DA-1241 in healthy male subjects and subjects with T2DM
- Trial name
- NCT03646721
- Testing
- DA-1241, Sitagliptin
- Where
- 4 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Diabetes Mellitus, Type 2
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
This study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2330672 compared to sitagliptin when administered with metformin for 14 days to subjects with type 2 diabetes…
- Trial name
- NCT02202161
- Testing
- GSK2330672, Sitagliptin, Metformin
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Type2 Diabetes, Myocardial Infarction
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events
The purpose of this study is to compare the risk of cardiovascular events associated with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in comparison with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors among…
- Conditions
- Type2 Diabetes, Myocardial Infarction, Ischemic Stroke, Cardiovascular Death
- Trial name
- NCT03939624
- Testing
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Where
- Canada
- Volunteers
- 419,734 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Bioequivalence
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fed Study.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL25-IC003 (NCT07763912)
- Testing
- Janumet XR, Sitagliptin/Metformin FDC
- Where
- Mexico
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ADIUM
Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation
Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation
Primary Objective: It is hypothesized that the efficacy of Sitagliptin would reduce the incidence of grade II-IV acute Graft Versus Host Disease (GVHD) by day +100 post-transplant in patients undergoing alternative donor (related…
- Trial name
- SHIELD (NCT05149365)
- Testing
- Sitagliptin + Standard Prophylaxis, Standard Prophylaxis
- Where
- China
- Volunteers
- 190 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Type 2 Diabetes Mellitus
A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin
The purpose of this study is to compare the efficacy and safety of ASP1941 50mg once daily in combination with metformin and sitagliptin against placebo in combination with metformin and sitagliptin over a 24 week treatment…
- Trial name
- NCT02452632
- Testing
- ASP1941
- Where
- 22 sites in South Korea
- Volunteers
- 143 people
- Sponsor
- Astellas Pharma Korea, Inc.
Diabetes Mellitus Type 2
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes.
- Trial name
- EPHIC-DIA2 (NCT06851962)
- Testing
- Metformin, Dulaglutide, Semaglutide 1.0 mg
- Where
- 3 sites in Spain
- Volunteers
- 92 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Type 2 Diabetes Mellitus
Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)
This is a randomized, double-blind, active control, parallel group, exploratory phase 4 study to compare the effect of teneligliptin versus sitagliptin on glucose variability when added on to metformin in patients with…
- Trial name
- NCT02512523
- Testing
- Teneligliptin, Sitagliptin
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Handok Inc.
Heart Failure, Diabetes Mellitus
DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure
We thought to investigate the influence of DPP-4 inhibitor on the serum BNP level of diabetic patients with congestive heart failure. This study consists of two protocols.
- Trial name
- NCT02312427
- Testing
- Suspending DPP-4 inhibitor, in outpatient service, Starting DPP-4 inhibitor after treatment of heart failure, Suspending DPP-4 inhibitor after treatment of heart failure
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Mitsui Memorial Hospital
Type 2 Diabetes
Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients
Triple combination of metformin, DPP4 inhibitor and Thiazolidinedione would be a good option in the treatment of drug-naïve Korean type 2 diabetic patients.
- Trial name
- NCT02188186
- Testing
- Initial triple combination, Conventional treatment
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Bundang Hospital
Type 2 Diabetes Mellitus, PreDiabetes
Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus
This study is conducted to examine GLP-1, insulin resistance and insulin sensitivity portfolio in Malay, Chinese and Indian populations in Malaysia and to study the effect of DPPIV inhibitor in T2DM patients with different…
- Trial name
- GLP-1 (NCT03659461)
- Testing
- Sitagliptin
- Where
- Malaysia
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
Type 2 Diabetes Mellitus
A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379
This is a randomized, open-label, single dose, crossover, phase Ⅰ trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-379 in healthy volunteers
- Trial name
- NCT06204107
- Testing
- CKD-379(Empagliflozin+sitagliptin+metformin) Test drug, CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Posttransplant Diabetes Mellitus
Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant
The purpose of this study is to determine whether sitagliptin is effective in preventing the development of new-onset diabetes after kidney transplant (NODAT).
- Trial name
- NCT01928199
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Type II Diabetes in Subjects BMI 27 to 32
Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment
Investigators aim to show that Roux-en-Y Gastric Bypass (RYGB) is superior to best medical treatment in reaching well-defined treatment end points in Asian subjects of BMI 27-32 with type 2 Diabetes (DM2).
- Trial name
- NCT02041234
- Testing
- Roux-en-Y Gastric Bypass (RYGB), Incretin analogues, Xenical
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Khoo Teck Puat Hospital
Patients
Drug Interaction Study Between Dorzagliatin and Sitagliptin
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and sitagliptin in subjects with T2DM.
- Trial name
- NCT03790839
- Testing
- Sitagliptin, Dorzagliatin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Hua Medicine Limited
Bioequivalance
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL25-IC004 (NCT07763951)
- Testing
- Janumet XR, Sitagliptin/Metformin FDC
- Where
- Mexico
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ADIUM
Type 2 Diabetes Mellitus
A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)
The purpose of this study is to assess the effect of the addition of sitagliptin (administered as MK-0431A or MK-0431A XR) relative to the addition of placebo on glycated hemoglobin (A1C), and the safety and tolerability of the…
- Trial name
- NCT01760447
- Testing
- Sitagliptin plus metformin, Metformin, Sitagliptin plus metformin XR
- Volunteers
- 223 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes, Overweight
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Conditions
- Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
- Trial name
- TIRZSEMA-CVOT (NCT07096063)
- Testing
- Tirzepatide, Dulaglutide, Semaglutide
- Where
- United States
- Volunteers
- 887,132 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes, Cardiovascular Disease
Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes
The goal of this study is to examine whether sitagliptin, an agent which enhances the action of hormones that control the release of insulin and is already in clinical use for type 2 diabetes, might also improve functional…
- Trial name
- NCT01951339
- Testing
- Sitagliptin, Glimepiride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Colorado, Denver
Liver Cirrhosis With Diabetes
Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis
This study was a prospective, interventional, two-part pilot clinical study conducted over 3 months on cirrhotic patients with diabetes mellitus and diabetic neuropathy, evaluating the real-world applicability of selected…
- Trial name
- NCT07439536
- Testing
- Sitagliptin (Januvia), Sitagliptin (JANUVIA®), Duloxetine (60 mg) once daily
- Where
- Egypt
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University